All In Biotech

Drug Trial Radar · NCT02352896

Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome

Long-Term Safety and Efficacy Evaluation of Vatiquinone (EPI-743) in Children With Leigh Syndrome

Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 31, 2014

Primary completion

Oct 30, 2023

Study completion Oct 30, 2023

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.

Conditions

  • Leigh Syndrome

Interventions

  • EPI-743Drug

    EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Severity as Measured by Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3 ScoreTime frame: Baseline up to Month 36
  2. Number of Participants With Dose-Limiting Serious Adverse Events (SAEs)Time frame: Baseline up to Month 36

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Gregory Enns

    Stanford University, California

  • Akron Children's Hospital

    Akron, Ohio

  • Baylor College of Medicine

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.